[go: up one dir, main page]

WO2002000638A3 - Nouveaux phthalides substitues, leur procede de preparation et compositions pharmaceutiques les contenant - Google Patents

Nouveaux phthalides substitues, leur procede de preparation et compositions pharmaceutiques les contenant Download PDF

Info

Publication number
WO2002000638A3
WO2002000638A3 PCT/IB2001/001535 IB0101535W WO0200638A3 WO 2002000638 A3 WO2002000638 A3 WO 2002000638A3 IB 0101535 W IB0101535 W IB 0101535W WO 0200638 A3 WO0200638 A3 WO 0200638A3
Authority
WO
WIPO (PCT)
Prior art keywords
group
substituted phthalides
convulsive drugs
convulsive
drugs
Prior art date
Application number
PCT/IB2001/001535
Other languages
English (en)
Other versions
WO2002000638A2 (fr
WO2002000638A8 (fr
Inventor
Zongru Guo
Fengming Chu
Juntian Zhang
Guangzhong Yang
Bailing Xu
Xinyi Niu
Zhihong Ren
Pierre Lestage
Pierre Renard
Original Assignee
Inst Materia Medica
Servier Lab
Zongru Guo
Fengming Chu
Juntian Zhang
Guangzhong Yang
Bailing Xu
Xinyi Niu
Zhihong Ren
Pierre Lestage
Pierre Renard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10/312,650 priority Critical patent/US6689808B2/en
Priority to SK106-2003A priority patent/SK1062003A3/sk
Priority to EA200300044A priority patent/EA200300044A1/ru
Priority to BR0112043-3A priority patent/BR0112043A/pt
Priority to NZ523174A priority patent/NZ523174A/en
Priority to CNB018120687A priority patent/CN100402515C/zh
Priority to JP2002505386A priority patent/JP2004501909A/ja
Priority to EP01958282A priority patent/EP1320528A2/fr
Priority to MXPA02012569A priority patent/MXPA02012569A/es
Priority to AU2001280004A priority patent/AU2001280004A1/en
Application filed by Inst Materia Medica, Servier Lab, Zongru Guo, Fengming Chu, Juntian Zhang, Guangzhong Yang, Bailing Xu, Xinyi Niu, Zhihong Ren, Pierre Lestage, Pierre Renard filed Critical Inst Materia Medica
Priority to CA002413752A priority patent/CA2413752A1/fr
Priority to HU0301567A priority patent/HUP0301567A3/hu
Publication of WO2002000638A2 publication Critical patent/WO2002000638A2/fr
Publication of WO2002000638A3 publication Critical patent/WO2002000638A3/fr
Priority to NO20026154A priority patent/NO20026154L/no
Publication of WO2002000638A8 publication Critical patent/WO2002000638A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des composés de formule (I): dans laquelle R1 représente un alkyle ou un groupe uréido, R2 représente un groupe alkyle ou un atome d'hydrogène, ou R1 et R2 forment ensemble un cycle à 5 ou 6 éléments, R3 signifie un groupe CN, NO¿2?, NRaR'a, NRaSO2R'a, NRaCZR5 ou CZNRaR'a, R?4¿ signifie un atome d'hydrogène ou un groupe R3.
PCT/IB2001/001535 2000-06-28 2001-06-27 Nouveaux phthalides substitues, leur procede de preparation et compositions pharmaceutiques les contenant WO2002000638A2 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
MXPA02012569A MXPA02012569A (es) 2000-06-28 2001-06-27 Ftalidas substituidas novedosas, un procedimiento para su preparacion y las composiciones farmaceuticas que contienen a las mismas.
EA200300044A EA200300044A1 (ru) 2000-06-28 2001-06-27 Новые замещенные фталиды, способ их получения и содержащие их фармацевтические композиции
BR0112043-3A BR0112043A (pt) 2000-06-28 2001-06-27 Ftalidas substituìdas, processo para sua preparação e composições farmacêuticas contendo-as
NZ523174A NZ523174A (en) 2000-06-28 2001-06-27 New substituted phthalides, a process for their preparation and pharmaceutical compositions containing them
CNB018120687A CN100402515C (zh) 2000-06-28 2001-06-27 用作抗惊厥药的取代2-苯并[c]呋喃酮
JP2002505386A JP2004501909A (ja) 2000-06-28 2001-06-27 抗けいれん薬としての置換フタリド類
EP01958282A EP1320528A2 (fr) 2000-06-28 2001-06-27 Substituierte phthalide als antikonvulsive medikamente
US10/312,650 US6689808B2 (en) 2000-06-28 2001-06-27 Substituted phthalides, a process for their preparations and pharmaceutical compositions containing them
SK106-2003A SK1062003A3 (en) 2000-06-28 2001-06-27 Substituted phthalides as anti-convulsive drugs
AU2001280004A AU2001280004A1 (en) 2000-06-28 2001-06-27 Substituted phthalides as anti-convulsive drugs
CA002413752A CA2413752A1 (fr) 2000-06-28 2001-06-27 Nouveaux phthalides substitues, leur procede de preparation et compositions pharmaceutiques les contenant
HU0301567A HUP0301567A3 (en) 2000-06-28 2001-06-27 Substituted phthalides as anti-convulsive drugs
NO20026154A NO20026154L (no) 2000-06-28 2002-12-20 Nye substituerte ftalider, fremgangsmåte for deres fremstilling og farmasöytiske sammensetninger inneholdende dem

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB001193295A CN1182127C (zh) 2000-06-28 2000-06-28 新的取代的2-苯并[c]呋喃酮化合物,其制备方法以及包含它们的药物组合物
CN00119329.5 2000-06-28

Publications (3)

Publication Number Publication Date
WO2002000638A2 WO2002000638A2 (fr) 2002-01-03
WO2002000638A3 true WO2002000638A3 (fr) 2002-05-23
WO2002000638A8 WO2002000638A8 (fr) 2003-08-28

Family

ID=4587601

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/001535 WO2002000638A2 (fr) 2000-06-28 2001-06-27 Nouveaux phthalides substitues, leur procede de preparation et compositions pharmaceutiques les contenant

Country Status (19)

Country Link
US (1) US6689808B2 (fr)
EP (1) EP1320528A2 (fr)
JP (1) JP2004501909A (fr)
KR (1) KR20030024710A (fr)
CN (2) CN1182127C (fr)
AR (1) AR030239A1 (fr)
AU (1) AU2001280004A1 (fr)
BR (1) BR0112043A (fr)
CA (1) CA2413752A1 (fr)
CZ (1) CZ2003245A3 (fr)
EA (1) EA200300044A1 (fr)
HU (1) HUP0301567A3 (fr)
MX (1) MXPA02012569A (fr)
NO (1) NO20026154L (fr)
NZ (1) NZ523174A (fr)
PL (1) PL359373A1 (fr)
SK (1) SK1062003A3 (fr)
WO (1) WO2002000638A2 (fr)
ZA (1) ZA200210004B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691420B2 (en) 2003-09-23 2010-04-06 Dsm Ip Assets B.V. Compositions for the treatment and prevention of diabetes mellitus
US8242168B2 (en) 2003-05-14 2012-08-14 Dsm Ip Assets B.V. Use of phthalide derivatives for the treatment of type 2 diabetes mellitus

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1605336A (zh) * 2003-10-10 2005-04-13 中国医学科学院药物研究所 左旋丁基苯酞在制备预防和治疗脑梗塞的药物中的应用
EP1757286B1 (fr) * 2004-06-18 2017-09-06 CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Utilisation de l-n-butylphthalide pour la prevention ou le traitement de la maladie d'alzheimer
CN102125548A (zh) * 2010-01-13 2011-07-20 石药集团恩必普药业有限公司 丁苯酞及其衍生物在制备治疗帕金森病的药物中的应用
CN102260233A (zh) * 2011-05-04 2011-11-30 武汉科技大学 3-丁基-1(3h)-异苯并呋喃酮衍生物及其制备方法
CN105367526B (zh) * 2015-10-14 2017-07-28 济南诚汇双达化工有限公司 一种高纯度正丁基苯酞的制备方法
CN108727352B (zh) * 2017-04-14 2021-04-23 四川大学 一类哌啶烷氨甲酰基苯酞类化合物、其制备方法和用途
WO2019179346A1 (fr) * 2018-03-19 2019-09-26 河南真实生物科技有限公司 Composés d'acide benzoïque, procédé de préparation associé et utilisations correspondantes
CN108752300B (zh) * 2018-05-16 2022-03-25 中国科学院昆明植物研究所 苄烯叉苯肽类化合物及其药物组合物和其应用
CN109111415B (zh) * 2018-10-25 2022-08-23 安徽中医药大学 一类石斛生物碱衍生物、制备方法和医药用途
CN112010827A (zh) * 2019-05-28 2020-12-01 四川大学 一类苄胺基苯酞类化合物、其制备方法和用途
CN112010837B (zh) * 2019-05-28 2021-12-17 四川大学 一类吡啶甲胺基苯酞类化合物、其制备方法和用途
CN110452203B (zh) * 2019-08-29 2021-04-13 忻州师范学院 一种1-氧代-1,3-二氢-3-羟基苯并呋喃-5-甲酸的制备方法
CN112794831B (zh) * 2021-04-06 2021-07-27 北京理工大学 3-(3′-羟基丁基)异苯并呋喃-1(3h)-酮衍生物及其组合物、制备方法和用途
CN119176789A (zh) * 2024-09-14 2024-12-24 中国药科大学 一种具有神经保护功能的含脒基新型iNOS抑制剂及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0151964A2 (fr) * 1984-02-02 1985-08-21 Laboratorio Farmaceutico C.T. s.r.l. Dérivés d'alpha-amino-gammabutyrolactone, procédé pour leur préparation et compositions pharmaceutiques les contenant
US4855320A (en) * 1986-05-05 1989-08-08 Dr. Willmar Schwabe Gmbh & Company 5-arylalkyl-4-alkoxy-2(5H)-furanones, intermediates and processes for the preparation thereof and medicaments containing them
EP0341081A2 (fr) * 1988-05-06 1989-11-08 Ono Pharmaceutical Co., Ltd. Dérivés amino-acides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW270133B (fr) * 1993-09-17 1996-02-11 Ciba Geigy
DE19618854A1 (de) * 1996-05-10 1997-11-13 Basf Ag Verfahren zur Herstellung von Phthaliden
DE19626659A1 (de) * 1996-07-03 1998-01-08 Basf Ag Verfahren zur Herstellung von Phthaliden

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0151964A2 (fr) * 1984-02-02 1985-08-21 Laboratorio Farmaceutico C.T. s.r.l. Dérivés d'alpha-amino-gammabutyrolactone, procédé pour leur préparation et compositions pharmaceutiques les contenant
US4855320A (en) * 1986-05-05 1989-08-08 Dr. Willmar Schwabe Gmbh & Company 5-arylalkyl-4-alkoxy-2(5H)-furanones, intermediates and processes for the preparation thereof and medicaments containing them
EP0341081A2 (fr) * 1988-05-06 1989-11-08 Ono Pharmaceutical Co., Ltd. Dérivés amino-acides

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8242168B2 (en) 2003-05-14 2012-08-14 Dsm Ip Assets B.V. Use of phthalide derivatives for the treatment of type 2 diabetes mellitus
US7691420B2 (en) 2003-09-23 2010-04-06 Dsm Ip Assets B.V. Compositions for the treatment and prevention of diabetes mellitus

Also Published As

Publication number Publication date
ZA200210004B (en) 2003-12-10
CN1330069A (zh) 2002-01-09
MXPA02012569A (es) 2004-05-17
SK1062003A3 (en) 2003-05-02
NO20026154L (no) 2003-02-20
US20030220393A1 (en) 2003-11-27
JP2004501909A (ja) 2004-01-22
CN1182127C (zh) 2004-12-29
CN1440398A (zh) 2003-09-03
WO2002000638A2 (fr) 2002-01-03
EA200300044A1 (ru) 2003-06-26
NO20026154D0 (no) 2002-12-20
US6689808B2 (en) 2004-02-10
HUP0301567A3 (en) 2005-08-29
CN100402515C (zh) 2008-07-16
CA2413752A1 (fr) 2002-01-03
AU2001280004A1 (en) 2002-01-08
AR030239A1 (es) 2003-08-13
KR20030024710A (ko) 2003-03-26
BR0112043A (pt) 2003-10-28
CZ2003245A3 (cs) 2003-05-14
PL359373A1 (en) 2004-08-23
EP1320528A2 (fr) 2003-06-25
WO2002000638A8 (fr) 2003-08-28
HUP0301567A2 (hu) 2003-09-29
NZ523174A (en) 2004-06-25

Similar Documents

Publication Publication Date Title
TW370450B (en) Substituted 1H-3-aryl-pyrrolidine-2,4-dione derivatives
WO2002000638A8 (fr) Nouveaux phthalides substitues, leur procede de preparation et compositions pharmaceutiques les contenant
BG103485A (en) Ketobanzamides as calpain inhibitors
DE69325454D1 (de) Taxol-derivate
TR200102957T2 (tr) Sitalopram hazırlanması için metod.
EP0513387A4 (en) Active oxygen inhibitor
WO1999000373A8 (fr) Derives de benzimidazole
NZ503912A (en) Piperidinylaminomethyl trifluoromethyl cyclic ether compounds and their use as substance P antagonists
EP0700291A4 (fr) 4-azasteroides a substitution en position 15
RS50229B (sr) Analozi vitamina d3
MY117092A (en) Chemotherapeutic pyrrolocarbazole derivatives
NZ330078A (en) Active oxygen carriers containing pterin derivatives and salts thereof for use as cosmetic agents and feed
ES8707525A1 (es) Un procedimiento para la preparacion de nuevas isoindolinil-alquilpiperazinas
TW427979B (en) A condensed piperidine compound
ES2093091T3 (es) Derivado de glutation.
WO2001009093A8 (fr) Derives de la benzenamine servant d'anticoagulants
EP0712398A1 (fr) Benzopyrans et compositions pharmaceutiques les contenant
EP0335979A4 (en) Thienopyrimidine derivatives
EP1020459A4 (fr) Derives d'aminocycloalkyle-pyrrolidine cis-disubstitues
EP0680960A4 (fr) Compose d'imidazole.
EP0997463A4 (fr) Derives de naphthyridine
EP0552489A3 (fr)
EP0394464A4 (en) Oxirane derivatives and herbicides containing same as active ingredients
GB9314355D0 (en) Novel compounds
TW334337B (en) Preparation and composition for a compound of controlling and preventing phytopathogenic fungi

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

CFP Corrected version of a pamphlet front page
WWE Wipo information: entry into national phase

Ref document number: 2001958282

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002/10004

Country of ref document: ZA

Ref document number: 200210004

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 523174

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/012569

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2001280004

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 10312650

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1020027017839

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2413752

Country of ref document: CA

Ref document number: 018120687

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 200300044

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: PV2003-245

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1062003

Country of ref document: SK

WWP Wipo information: published in national office

Ref document number: 1020027017839

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2003-245

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2001958282

Country of ref document: EP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 01/2002 UNDER (72, 75) THE ADDRESS OF "LESTAGE, PIERRE" SHOULD READ

Free format text: IN PCT GAZETTE 01/2002 UNDER (72, 75) THE ADDRESS OF "LESTAGE, PIERRE" SHOULD READ "9, ALLEE DE LA GTRANDE TERRE, F-78150 LA CELLESAINT CLAUD (FR)." AND THE ADDRESS OF "RENARD, PIERRE" SHOULD RESD "3, AVENUE DU PARC, F-78150 LE CHESNAY (FR)."

WWW Wipo information: withdrawn in national office

Ref document number: 2001958282

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 523174

Country of ref document: NZ

WWR Wipo information: refused in national office

Ref document number: PV2003-245

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 523174

Country of ref document: NZ

WWR Wipo information: refused in national office

Ref document number: 1020027017839

Country of ref document: KR